Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
+1 212 318 2000
Europe, Middle East, & Africa
+44 20 7330 7500
+65 6212 1000
Watson Pharmaceuticals Inc. said Tuesday it received marketing approval for a generic version of Bayer's oral contraceptive Yasmin.
Watson said it has started shipping the drug under the brand name Zarah after getting clearance from the Food and Drug Administration. Bayer is suing Watson for patent infringement.
Watson said sales of Yasmin and its other generic equivalents totaled $97 million over the year ended June 30, according to IMS Health data.